Repare Therapeutics (RPTX) Projected to Post Earnings on Wednesday

Repare Therapeutics (NASDAQ:RPTX) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Repare Therapeutics Stock Down 2.3 %

NASDAQ:RPTX opened at $1.26 on Tuesday. Repare Therapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $7.45. The stock has a market cap of $53.56 million, a PE ratio of -0.63 and a beta of 0.88. The firm’s fifty day simple moving average is $1.27 and its 200-day simple moving average is $2.53.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on RPTX shares. Stifel Nicolaus lowered their price target on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Lifesci Capital restated a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a report on Friday, November 8th. Finally, Bloom Burton lowered shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.